Vimarsana
Biggest News Aggregation in the World

Page 16 - Repligen Corp News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Repligen Corp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Repligen Corp Today - Breaking & Trending Today

Ouster Opts for Cuts to Reduce Costs: Week in Brief: 09/23/22 | Business | Sep 2022 - Vimarsana News

Ouster Opts for Cuts to Reduce Costs: Week in Brief: 09/23/22 | Business | Sep 2022

Ouster, a provider of high-resolution digital lidar sensors, enacted a comprehensive cost reduction initiative, streamlining its cost structure and ex

Bioprocess Technology Market to record USD 55.84 Bn growth -- Evolving Opportunities with Advanced Instruments LLC and Becton Dickinson and Co. - Vimarsana News

Bioprocess Technology Market to record USD 55.84 Bn growth -- Evolving Opportunities with Advanced Instruments LLC and Becton Dickinson and Co.

/PRNewswire/ -- The "Bioprocess Technology Market by End-user and Geography - Forecast and Analysis 2022-2026" report has been added to Technavio's offering....

Repligen: Q2 Earnings Snapshot - Vimarsana News

Repligen: Q2 Earnings Snapshot

WALTHAM, Mass. (AP) _ Repligen Corp. (RGEN) on Tuesday reported second-quarter net income of $49.9 million. The Waltham, Massachusetts-based company said it had profit of 88 cents per share. Earnings, adjusted for non-recurring costs, were 91 cents per share.

Source: apnews.com
Life sciences industry drives activity in Q2 office market - Vimarsana News

Life sciences industry drives activity in Q2 office market

Office leasing gained some in Q2, seeing 2.8 million square feet of activity, according to Colliers, driven by life sciences.

Source: njbiz.com
Rapid method development to overcome challenges of bi-specific antibody purification - Vimarsana News

Rapid method development to overcome challenges of bi-specific antibody purification

Stuart Jamieson and Alice Harrison at Lonza discuss rapid method development to overcome the challenges of bi-specific antibody purification.